Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $162.70, for a total transaction of $113,890.00. Following the sale, the chief financial officer now directly owns 33,468 shares of the company’s stock, valued at $5,445,243.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
JAZZ traded up $3.44 on Friday, hitting $158.82. 768,222 shares of the company’s stock were exchanged, compared to its average volume of 481,001. The firm has a market cap of $10.16 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 0.92 and a beta of 1.04. Jazz Pharmaceuticals PLC has a twelve month low of $128.58 and a twelve month high of $184.00. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.23 by $0.26. The firm had revenue of $500.48 million for the quarter, compared to analyst estimates of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current year.
JAZZ has been the subject of a number of research reports. BMO Capital Markets upped their price target on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 8th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, July 8th. BidaskClub cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 18th. Citigroup upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 10th. Finally, Morgan Stanley cut shares of Jazz Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $183.00 price objective for the company. in a research report on Wednesday, July 11th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $192.11.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Diversification in Your Portfolio
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.